Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
作者信息
Kim Sandra, St-Laurent Marie-Pier, Black Peter
机构信息
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
出版信息
Transl Androl Urol. 2024 Mar 31;13(3):458-462. doi: 10.21037/tau-23-620. Epub 2024 Mar 12.
Abstract
摘要
相似文献
1
Biomarker challenges in the pursuit of personalized neoadjuvant chemotherapy for muscle-invasive bladder cancer: conclusions from SWOG S1314.
Transl Androl Urol. 2024 Mar 31;13(3):458-462. doi: 10.21037/tau-23-620. Epub 2024 Mar 12.
2
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.
Bladder Cancer. 2020 Jun 11;6(2):123-129. doi: 10.3233/BLC-190266.
3
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
Clin Cancer Res. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10.
4
Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314.
Eur Urol Focus. 2022 May;8(3):648-650. doi: 10.1016/j.euf.2022.03.013. Epub 2022 Mar 23.
5
Neoadjuvant chemotherapy in patients with invasive bladder cancer.
Urol Clin North Am. 2005 May;32(2):231-7. doi: 10.1016/j.ucl.2005.03.001.
6
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Eur Urol. 2022 Aug;82(2):212-222. doi: 10.1016/j.eururo.2022.04.013. Epub 2022 May 14.
7
Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
Methods Mol Biol. 2023;2684:229-247. doi: 10.1007/978-1-0716-3291-8_14.
8
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.
J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18.
9
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
J Urol. 2014 Apr;191(4):898-906. doi: 10.1016/j.juro.2013.10.142. Epub 2013 Dec 1.
10
Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.
Jpn J Clin Oncol. 2022 Apr 6;52(4):388-396. doi: 10.1093/jjco/hyab210.
本文引用的文献
1
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Clin Cancer Res. 2024 Jan 17;30(2):444-449. doi: 10.1158/1078-0432.CCR-23-0602.
2
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Clin Cancer Res. 2023 Dec 1;29(23):4797-4807. doi: 10.1158/1078-0432.CCR-23-1860.
3
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Eur Urol. 2023 Sep;84(3):341-347. doi: 10.1016/j.eururo.2023.06.014. Epub 2023 Jul 4.
4
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Eur Urol Oncol. 2023 Oct;6(5):516-524. doi: 10.1016/j.euo.2023.03.008. Epub 2023 Apr 20.
5
Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2023 Apr 14;29(8):1582-1591. doi: 10.1158/1078-0432.CCR-22-3250.
6
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.
Eur Urol. 2023 Apr;83(4):313-317. doi: 10.1016/j.eururo.2022.07.023. Epub 2022 Aug 11.
7
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7.
8
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
Clin Cancer Res. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10.
9
Enhanced Co-Expression Extrapolation (COXEN) Gene Selection Method for Building Anti-Cancer Drug Response Prediction Models.
Genes (Basel). 2020 Sep 11;11(9):1070. doi: 10.3390/genes11091070.
10
Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2020 Aug;3(4):544-547. doi: 10.1016/j.euo.2020.02.003. Epub 2020 Mar 10.
Zotero 插件